Thrombosis
May 10, 2013 10:00 EDT
The Watchman left-atrial appendage occluder had previously been found noninferior to warfarin in patients with nonvalvular atrial fibrillation; now, with an average of 45 months of follow-up, it's not only noninferior, it's superior, by some statistical measures.

Denver, CO - A long-term follow-up analysis of the PROTECT-AF trial shows—in contrast to shorter-term analyses based on the trial—that left atrial appendage (LAA) closure with the Watchman (Boston Scientific) is superior to warfarin with respect to all-cause and CV mortality and hemorrhagic stroke in patients with nonvalvular atrial fibrillation and stroke risk factors [1].
Read full article »

Editorial programs
Debate and dialogue between top cardiovascular specialists, produced by
theheart.org's editorial team
View all »
View all »Collections
heartwire collections groups our most compelling cardiology news coverage and editorial content by popular themes. Find everything on a single topic, in one place, with one click.
The quest for ever-more effective drugs to decrease platelet aggregation and reduce the...
Long considered an essential agent for primary cardiovascular disease prevention...
The presentation of the RE-LY results at the 2009 ESC meeting, showing that dabigatran...
Magnetic resonance imaging tests are increasingly being used for diagnosing forms of...
Heart disease still tops the charts as the number-one killer in most developed...